FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 169 filers reported holding FATE THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 9.78 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $35,077 | -72.8% | 16,546 | -38.9% | 0.00% | – |
| Q2 2023 | $128,977 | -98.8% | 27,096 | -94.5% | 0.00% | -100.0% |
| Q3 2022 | $10,949,000 | -33.3% | 488,558 | -26.3% | 0.01% | -25.0% |
| Q2 2022 | $16,424,000 | -36.2% | 662,813 | -0.2% | 0.01% | -20.0% |
| Q1 2022 | $25,743,000 | -35.6% | 663,999 | -2.8% | 0.01% | -28.6% |
| Q4 2021 | $39,984,000 | -2.1% | 683,372 | -0.8% | 0.01% | -6.7% |
| Q3 2021 | $40,825,000 | -32.4% | 688,804 | -1.1% | 0.02% | -34.8% |
| Q2 2021 | $60,435,000 | -3.2% | 696,336 | -8.1% | 0.02% | -8.0% |
| Q1 2021 | $62,458,000 | -9.0% | 757,532 | +0.3% | 0.02% | -13.8% |
| Q4 2020 | $68,647,000 | +53.7% | 754,942 | -32.4% | 0.03% | +31.8% |
| Q3 2020 | $44,652,000 | +15.6% | 1,117,142 | -2.8% | 0.02% | +10.0% |
| Q2 2020 | $38,624,000 | +51.2% | 1,149,864 | -0.0% | 0.02% | +17.6% |
| Q1 2020 | $25,547,000 | -26.0% | 1,150,239 | -34.8% | 0.02% | -5.6% |
| Q4 2019 | $34,518,000 | -4.1% | 1,763,821 | -23.9% | 0.02% | -10.0% |
| Q3 2019 | $36,010,000 | -39.7% | 2,318,721 | -21.1% | 0.02% | -37.5% |
| Q2 2019 | $59,693,000 | +6.1% | 2,940,521 | -8.2% | 0.03% | +6.7% |
| Q1 2019 | $56,277,000 | +35.2% | 3,203,021 | -1.3% | 0.03% | +20.0% |
| Q4 2018 | $41,630,000 | -52.3% | 3,244,706 | -39.4% | 0.02% | -41.9% |
| Q3 2018 | $87,286,000 | +39.2% | 5,358,265 | -3.1% | 0.04% | +34.4% |
| Q2 2018 | $62,719,000 | +9.9% | 5,530,749 | -5.4% | 0.03% | +10.3% |
| Q1 2018 | $57,084,000 | +54.8% | 5,848,779 | -3.1% | 0.03% | +61.1% |
| Q4 2017 | $36,879,000 | +53.3% | 6,035,779 | -0.7% | 0.02% | +50.0% |
| Q3 2017 | $24,064,000 | +22.2% | 6,076,879 | 0.0% | 0.01% | +20.0% |
| Q2 2017 | $19,689,000 | -28.8% | 6,076,879 | 0.0% | 0.01% | -28.6% |
| Q1 2017 | $27,650,000 | +83.3% | 6,076,879 | 0.0% | 0.01% | +75.0% |
| Q4 2016 | $15,084,000 | -9.2% | 6,076,879 | +14.1% | 0.01% | -11.1% |
| Q3 2016 | $16,614,000 | +1854.6% | 5,325,000 | +965.0% | 0.01% | – |
| Q2 2016 | $850,000 | -5.6% | 500,000 | 0.0% | 0.00% | – |
| Q1 2016 | $900,000 | -46.6% | 500,000 | 0.0% | 0.00% | -100.0% |
| Q4 2015 | $1,685,000 | -36.8% | 500,000 | 0.0% | 0.00% | 0.0% |
| Q3 2015 | $2,665,000 | -17.6% | 500,000 | 0.0% | 0.00% | 0.0% |
| Q2 2015 | $3,235,000 | – | 500,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $131,006,000 | 24.77% |
| Redmile Group, LLC | 12,957,222 | $502,351,000 | 15.68% |
| Grosvenor Holdings, L.L.C. | 1,037,256 | $40,214,000 | 7.85% |
| Casdin Capital, LLC | 3,400,000 | $131,818,000 | 5.91% |
| Ally Bridge Group (NY) LLC | 181,500 | $7,037,000 | 5.22% |
| DAFNA Capital Management LLC | 500,930 | $19,421,000 | 5.06% |
| Deep Track Capital, LP | 2,000,000 | $77,540,000 | 4.97% |
| Artal Group S.A. | 2,000,000 | $77,540,000 | 3.25% |
| Tri Locum Partners LP | 190,345 | $7,380,000 | 2.88% |
| ARK Investment Management | 10,988,182 | $426,012,000 | 1.78% |